TERN
Income statement / Annual
Last year (2024), Terns Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Terns Pharmaceuticals, Inc.'s net income was -$88.85 M.
See Terns Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$1.00 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$195.00 K
|
$65.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$1.00 M
|
$0.00
|
-$195.00 K
|
-$65.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$70.11 M
|
$63.50 M
|
$39.62 M
|
$31.31 M
|
$28.03 M
|
$61.53 M
|
$14.55 M
|
| General & Administrative Expenses |
$31.76 M
|
$39.06 M
|
$22.41 M
|
$19.55 M
|
$9.00 M
|
$8.66 M
|
$3.90 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$31.76 M
|
$39.06 M
|
$22.41 M
|
$19.55 M
|
$9.00 M
|
$8.66 M
|
$3.90 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$154.00 K
|
$38.00 K
|
| Operating Expenses |
$101.87 M
|
$102.56 M
|
$62.03 M
|
$50.86 M
|
$37.03 M
|
$70.20 M
|
$18.46 M
|
| Cost And Expenses |
$101.87 M
|
$102.56 M
|
$62.03 M
|
$50.86 M
|
$37.03 M
|
$70.20 M
|
$18.46 M
|
| Interest Income |
$13.29 M
|
$12.90 M
|
$2.11 M
|
$170.00 K
|
$55.00 K
|
$1.20 M
|
$332.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$896.00 K
|
$881.00 K
|
$1.03 M
|
$512.00 K
|
$394.00 K
|
$195.00 K
|
$65.00 K
|
| EBITDA |
-$100.98 M |
-$101.68 M |
-$61.00 M |
-$49.35 M |
-$36.63 M |
-$68.64 M |
-$18.39 M |
| EBITDA Ratio |
0
|
0
|
0
|
-49.35
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-49.86
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$13.28 M
|
$12.59 M
|
$2.04 M
|
$210.00 K
|
$7.97 M
|
$1.36 M
|
$370.00 K
|
| Income Before Tax |
-$88.59 M
|
-$89.97 M
|
-$59.99 M
|
-$49.65 M
|
-$29.06 M
|
-$68.84 M
|
-$18.09 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-49.65
|
0
|
0
|
0
|
| Income Tax Expense |
$260.00 K
|
$239.00 K
|
$358.00 K
|
$508.00 K
|
$813.00 K
|
-$20.00 K
|
-$67.00 K
|
| Net Income |
-$88.85 M
|
-$90.21 M
|
-$60.35 M
|
-$50.16 M
|
-$29.35 M
|
-$68.82 M
|
-$17.71 M
|
| Net Income Ratio |
0
|
0
|
0
|
-50.16
|
0
|
0
|
0
|
| EPS |
-1.12 |
-1.27 |
-1.67 |
-1.98 |
-1.61 |
-2.74 |
-0.74 |
| EPS Diluted |
-1.12 |
-1.27 |
-1.67 |
-1.98 |
-1.61 |
-2.74 |
-0.74 |
| Weighted Average Shares Out |
$79.51 M
|
$71.26 M
|
$36.03 M
|
$25.27 M
|
$25.13 M
|
$25.10 M
|
$23.97 M
|
| Weighted Average Shares Out Diluted |
$79.51 M
|
$71.26 M
|
$36.03 M
|
$25.27 M
|
$25.13 M
|
$25.10 M
|
$23.97 M
|
| Link |
|
|
|
|
|
|
|
